Log In
BCIQ
Print this Print this
 

Erwinase, Erwinaze

  Manage Alerts
Collapse Summary General Information
Company Jazz Pharmaceuticals plc
DescriptionErwinia chrysanthemi-derived L-asparaginase
Molecular Target
Mechanism of Action 
Therapeutic ModalityBiologic: Enzyme
Latest Stage of DevelopmentMarketed
Standard IndicationAcute lymphoblastic leukemia (ALL)
Indication DetailsTreat acute lymphoblastic leukemia (ALL) in patients with hypersensitivity to Escherichia coli-derived asparaginase
Regulatory Designation U.S. - Orphan Drug (Treat acute lymphoblastic leukemia (ALL) in patients with hypersensitivity to Escherichia coli-derived asparaginase);
U.S. - Priority Review (Treat acute lymphoblastic leukemia (ALL) in patients with hypersensitivity to Escherichia coli-derived asparaginase)
PartnerOhara Pharmaceutical Co. Ltd.;
Porton Biopharma Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

$700.0M

$650.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

06/18/2012

$700.0M

$650.0M

0

07/12/2010

Undisclosed

Undisclosed

0

Get a free BioCentury trial today